GLP-1受体激动剂降脂作用机制及临床应用的研究进展

中图分类号R972+.6;R96 文献标志码A 文章编号1001-0408（2025）20-2615-06

DOI 10.6039/j.issn.1001-0408.2025.20.23

Research progresson the lipid-lowering mechanisms and clinical application of GLP-1 receptor agonists ZHU Yanjiao’，GAO Rui1，ZONG Huiying2，LI An'an²，ZHOU Penglin2，HE Shuai²，WU Xichao²，LI Yan[1.Dept. ofPharmacy，theFirst Afiliated Hospital of Shandong First Medical University（ShandongProvincial Qianfoshan Hospital）/Shandong Engineering and Technology Research Center for Clinical Evaluationand Development of Pediatric Drugs/Shandong Medicine and Health Key Laboratory of Clinical Pharmacy，Jinan 250014，China;2. School of Pharmacy，Shandong University of Traditional Chinese Medicine，Jinan 250355， China]

ABSTRACTGlucagon-likepeptide-1（GLP-1）receptoragonistsareanovelclassofantidiabeticdrugsthatalsoposess lipidloweringandcardiovascularprotectiveeffects，withliraglutideandsemaglutidebeingtheirrepresentativemedications.Basedona systematicliteraturesearch，thisreviewsummarizesthelipid-loweringmechanismsbywhichliraglutideandsemaglutideexertdirect efectsontheliverandkidney（regulatingautophagy，keylipidmetabolismpathways，reversecholesteroltransport，etc.），direct actionsonadiposetissue（afectingadipocyteproliferationanddiferentiation，expressonoflipidmetabolismprotens，andgene transcription），activationof sympatheticpathways through thecentral nervoussystem，andmodulationofthegut microbiota. Aditionally，itsummarizestheclinicalevidenceoftheirlipid-loweringefectsinpopulationswithtype2diabetesmelius， overweightindividuals，ndothers.ThesefindingsindicatethatGLP-1reeptoragonistsexertlipid-loweringefectsbyactingon multipletissuesorsystems，providing crucialevidence forfurther elucidatingthemolecularmechanismsofthesedrugs inlipid regulation and exploring potential new ideas for their clinical applications.

KEYWORDSGLP-1receptoragonists；lipid-lowering efect；mechanism；clinicalresearch；iraglutide；semaglutide

胰高血糖素样肽1（glucagon-likepeptide-1，GLP-1）受体激动剂是一类新型降糖药物，主要用于治疗2型糖尿病（type2diabetesmellitus，T2DM）[1]。（剩余15442字）